BioSpace News Archive

Genentech, a member of the Roche Group, announced results from the primary analysis of the Phase III ALINA study demonstrating a statistically significant and clinically meaningful improvement in disease-free survival.

Sensorion is pleased to announce its participation, in-person, in the European Society of Gene & Cell Therapy conference, taking place on October 24-27, 2023, in Brussels, Belgium.

The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.

Aculys Pharma, Inc. announced that it has achieved its primary efficacy endpoint in a pre-specified interim analysis of its Phase 3 clinical study of a diazepam nasal spray, an antiepileptic drug for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus targeting Japanese patients aged 6 to 17 years.

Sosei Group Corporation is pleased to announce its President & CEO, Chris Cargill has won Executive of the Year for the second year running at the Citeline Pharma Intelligence Awards Japan 2023 held yesterday in Tokyo.

Gilead Sciences, Inc. announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe.

Telix Pharmaceuticals Limited issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023.

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.

TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine

Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for chronic pain, has taken a significant step forward with the commencement of dosing for the initial participants in its Phase 1 clinical trial, designated MBR01T-101.